Saama leverages advanced technologies such as artificial intelligence (AI), Generative AI, and advanced analytics to enhance clinical development and commercialization processes. Their solutions are designed to automate key tasks, significantly reducing the time and effort required for data discovery, protocol generation, and report creation. For instance, Saama's Smart Data Quality (SDQ) tool has saved over 20,000 hours of manual work, while their Source to Submission (S2S) solution has achieved up to 50% time savings in transforming data for regulatory submissions. The company’s focus on AI-driven SaaS solutions allows for efficient data management and insights, ultimately accelerating the delivery of therapies to patients.

In addition to their core offerings, Saama has developed specialized tools like the Biometrics Research and Analysis Information Network (BRAIN), which centralizes statistical programming and biostatistics workflows. This platform enhances submission timelines by providing a single environment for managing data, programming, and artifacts, while ensuring full traceability of changes through a proprietary knowledge graph. Saama's commitment to innovation is further demonstrated by their Clinical GenAI Innovation Labs, which facilitate rapid experimentation and development of AI models tailored to the clinical lifecycle. With a decade of experience and numerous patents, Saama positions itself as a leader in applying AI to solve complex challenges in the life sciences sector.

United States

Saama develops life science solutions that accelerate the delivery of therapies to patients. With innovative AI technologies, Saama drives breakthrough intelligence into clinical and commercial operations. The Saama platform powered the clinical trial that led to the world’s first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives. Discover more at saama.com.

Saama

Company Details